|
Head and neck cancer
|
- Decreased PTEN expression in 30% of patients
|
[154]
|
|
Glioblastoma
|
- Loss of heterozygosity of PTEN in 60%–80% of patients
|
[155]
|
|
- PTEN mutations in up to 40% of patients
|
|
Breast cancer
|
- PTEN mutations in 3% of patients
|
[156, 157]
|
|
- Loss of PTEN protein in 30% of patients
|
|
Ovarian cancer
|
- Loss of heterozygosity of PTEN in 45% of endometrioid carcinoma of the ovary
|
[158]
|
|
Non-small cell lung cancers
|
- Loss of PTEN protein expression in 75% of patients
|
[159]
|
|
Endometrial cancer
|
- Mutation or reduction of heterozygosity in 55% of patients
|
[160]
|
|
Colorectal cancer
|
- Loss of PTEN protein expression in 20%-40% of patients
|
[161]
|
|
Prostate cancer
|
- PTEN mutations in 15% of primary tumours, 20% of localised tumours and 50% of hormone-refractory cancer patients
|
[162]
|
